Good Morning All14 Jun 2018 09:54
To me ,the most significant part of today's RNS is the statement that New Zealand has accepted Patent for VAL-401 for use in pancreatic cancer.This disease has the highest mortality and is very resistant to any therapy.With VAL-401 such patients will derive great benefits with regard to quality of their remaining lifes.As it stands with regards to research thus far, it is also possible that in addition, their lives could be extended too.So there is some good in this RNS,a positive development.GLA - Stach